Canopy Growth Corporation (TSX:WEED) acquired C3 - Cannabionoid Compound Company GmbH from Bionorica SE for approximately €230 million on April 30, 2019. The consideration was paid in cash. The existing facilities in Neumarkt, Frankfurt and Vienna will continue to operate. In 2018, C3 - Cannabionoid Compound Company achieved sales of approximately €27.1 million. C3 - Cannabionoid Compound Company's senior management team includes; Josef Harrer, Head of Business Development and Medical Marketing at Bionorica ethics; Kristin Mann, Head of Marketing and Sales, Anna Urlacher, Chief Financial Officer, and Silvia Heise-Grubner, Head of Austrian operations. All four will continue to drive the business post-closing, accepting leadership roles in Canopy Growth Corporation. Nils Rahlf, Heiko Bertelmann, Marco Niehaus, Christoph Ritzer, Frank Weberndörfer, Hendrik Theismann, Maxim Kleine, Daniel Marschollek, Clemens Rübel, Michael Mehler, Tim Schaper, Manuel Merling, Uwe Eppler, Tino Duttiné, Michael Wiedmann, Felix Dinger, Tiffany Zilliox, Sven Jacobs, Andre Hartmann, Daniela Kowalsky, Maria Siemens, Christoph Valentin, Katja Weiß, Tobias Teichner, Natalia Filkina, Alisa Kuznetsova, Maximilian Schmitz, Julia Gallinger, Judith Kutter, Robert Schmidt, Graf Patsch Taucher and Bernd Taucher of Norton Rose Fulbright Canada LLP acted as legal advisors to Canopy Growth. Stephan Zuber, Jörg Maitzen, Michael Emig, Frank Stahl, Robert Rostek, Christine Ostwald, Jens Füller, Katja Fleschütz and Daniel Stix of Baker Tilly Rechtsanwaltsgesellschaft mbH acted as legal advisors to Bionorica SE. Lincoln International AG acted as a legal advisor to Bionorica SE in the transaction. Ernst & Young GmbH provided due diligence to Bionorica SE. Canopy Growth Corporation (TSX:WEED) completed the acquisition of C3 - Cannabionoid Compound Company GmbH from Bionorica SE on April 30, 2019.